-
再生医療（AMED）
分担研究者：東北大学 加藤幸成（代表：京都大学 金子 新）
令和２年度（9月1日）〜令和４年度
課題名：次世代型ヒト人工染色体ベクターによるCAR交換型高機能再生T細胞治療の開発拠点
東北大学ではこれまで、がん細胞に特異的な反応性を示すモノクローナル抗体の作製法（CasMab法）を用いることにより、ポドプラニンに対して、複数のCasMabの作製に成功した。ポドプラニンはリンパ管内皮細胞、肺胞上皮細胞、皮膚基底細胞、腎上皮細胞などの全身の正常細胞に高発現し、通常の抗体では様々な副作用が懸念される。CasMabはそれらの正常細胞に反応せず、肺がん、食道がん、悪性中皮腫、悪性脳腫瘍、卵巣がんなどの複数の難治性がんに高い反応性を示すため、抗体医薬の新規ターゲットとして期待される。さらに、乳がんや膵がんの他に血管内皮細胞などの正常細胞にも高発現しているポドカリキシンに対しても、がん特異的な反応性を示すCasMabを複数作製してきた。本プロジェクトにおいては、ポドプラニンやポドカリキシンに対するCasMabをヒト化あるいはscFv化し、CAR-Tに搭載できるフォーマットへの最適化を行う。
-
＜文献＞
2023
32. Suzuki H, Tanaka T, Goto N, Kaneko MK, Kato Y.
Development of a novel anti-CD44 variant 4 monoclonal antibody C44Mab-108 for immunohistochemistry
Curr. Issues Mol. Biol., 45(3), 1875-1888; https://doi.org/10.3390/cimb45030121, 2023 (PDF)
31. Ryo Ejima, Hiroyuki Suzuki, Tomohiro Tanaka, Teizo Asano, Mika K. Kaneko, Yukinari Kato
Development of a Novel Anti-CD44 variant 6 Monoclonal Antibody C44Mab-9 for Multiple Applications against Colorectal Carcinomas
Int. J. Mol. Sci., 24(4), 4007; https://doi.org/10.3390/ijms24044007, 2023 (PDF)
30. Kobayashi H, Asano T, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
Determination of the Binding Epitope of an Anti-mouse CCR9 Monoclonal Antibody (C9Mab-24) using the 1 × alanine and 2 × alanine-substitution Method
antibodies, 12(1), 11; https://doi.org/10.3390/antib12010011, 2023 (PDF)
29. Guanjie Li, Hiroyuki Suzuki, Tomokazu Ohishi, Teizo Asano, Tomohiro Tanaka, Miyuki Yanaka, Takuro Nakamura, Takeo Yoshikawa, Manabu Kawada, Mika K. Kaneko, Yukinari Kato.
Antitumor activities by a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models
Int J Mol Med, 51(2), 18, https://doi.org/10.3892/ijmm.2023.5221, 2023 (PDF)
28. Tomokazu Ohishi, Mika K. Kaneko, Yukihiko Yoshida, Atsuo Takashima, Yukinari Kato, Manabu Kawada
Current targeted therapy for metastatic colorectal cancer
Int. J. Mol. Sci. , 24(2), 1702; https://doi.org/10.3390/ijms24021702, 2023 (PDF)
2022
27. Asano T, Tanaka T, Suzuki H, Li G, Nanamiya R, Tateyama N, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Development of a Novel Anti-Mouse CCR6 Monoclonal Antibody (C6Mab-13) by N-Terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 343–349, doi: 10.1089/mab.2022.0021, 2022 (PDF)
26. Tanaka T, Suzuki H, Asano T, Li G, Nanamiya R, Tateyama N, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Epitope mapping of an Anti-Mouse CCR2 Monoclonal Antibody (C2Mab-6) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 339–342, doi:10.1089/mab.2022.0020, 2022 (PDF)
25. Saito M, Suzuki H, Tanaka T, Asano T, Kaneko MK, Kato Y.
Development of an Anti-Mouse CCR8 Monoclonal Antibody (C8Mab-1) for Flow cytometry and Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 333–338, https://doi.org/10.1089/mab.2021.0069, 2022 (PDF)
24. Kawabata H, Ohishi T, Suzuki H, Asano T, Kawada M, Suzuki H, Kaneko MK, Kato Y.
A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG2a-f) Exerts Antitumor Activity in a Mouse Xenograft Model of Renal Cell Cancers
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 320–327, https://doi.org/10.1089/mab.2021.0049, 2022 (PDF)
23. Nanamiya R, Suzuki H, Takei J, Li G, Goto N, Harada H, Saito M, Tanaka T, Asano T, Kaneko MK, Kato Y.
Development of Monoclonal Antibody 281-mG2a-f Against Golden Hamster Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 311–319, https://doi.org/10.1089/mab.2021.0058, 2022 (PDF)
22. Tanaka T, Suzuki H, Isoda Y, Asano T, Nakamura T, Yanaka M, Handa S, Takahashi N, Okuno S, Yoshikawa T, Li G, Nanamiya R, Goto N, Tateyama N, Okada Y, Kobayashi H, Kaneko MK, Kato Y.
Development of a Sensitive Anti-human CCR9 Monoclonal Antibody (C9Mab-11) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 303–310, doi: 10.1089/mab.2022.0027, 2022 (PDF)
21. Nami Tateyama, Teizo Asano, Hiroyuki Suzuki, Guanjie Li, Takeo Yoshikawa, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato
Epitope Mapping of Anti-mouse CCR3 Monoclonal Antibodies using Flow Cytometry
antibodies, 11(4), 75; https://doi.org/10.3390/antib11040075, 2022 (PDF)
20. Teizo Asano, Tomohiro Tanaka, Hiroyuki Suzuki, Guanjie Li, Tomokazu Ohishi, Manabu Kawada, Takeo Yoshikawa, Mika K. Kaneko, Yukinari Kato
A Defucosylated Anti-EpCAM Monoclonal Antibody (Ep-Mab-37-mG2a-f) Exerts Antitumor Activity in Xenograft Model
antibodies, 11(4), 74; https://doi.org/10.3390/antib11040074, 2022 (PDF)
19. Tateyama N, Suzuki H, Ohishi T, Asano T, Tanaka T, Mizuno T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y.
Antitumor Activity of an anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
pharmaceutics,14(11), 2494; https://doi.org/10.3390/pharmaceutics14112494, 2022 (PDF)
18. Isoda Y, Tanaka T, Suzuki H, Asano T, Nakamura T, Yanaka M, Handa S, Komatsu Y, Okuno S, Takahashi N, Okada Y, Kobayashi H, Li G, Nanamiya R, Goto N, Tateyama N, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-mouse CXCR6 Monoclonal Antibody (Cx6Mab-1) using the 2×Alanine scanning method
Monoclon. Antib. Immunodiagn. Immunother.,41(5),275–278, DOI: 10.1089/mab.2022.0019, 2022 (PDF)
17. Tanaka T, Suzuki H, Li G, Nanamiya R, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of the Anti-Human CCR2 Monoclonal Antibody (K036C2)
Monoclon. Antib. Immunodiagn. Immunother.,41(5),285–289, DOI: 10.1089/mab.2022.0018, 2022 (PDF)
16. Saito M, Suzuki H, Asano T, Tanaka T, Yoshikawa T, Kaneko MK, Kato Y.
KLMab-1: An Anti-Human KLRG1 Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother.,41(5),279–284, https://doi.org/10.1089/mab.2022.0016, 2022 (PDF)
15. Ishikawa A, Waseda M, Ishii T, Kaneko MK, Kato Y, Kaneko S.
Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in animal model
Genes Cells,27(9), 549-558, https://doi.org/10.1111/gtc.12972, 2022 (PDF)
14. Tanaka T, Li G, Saito M, Suzuki H, Asano T, Kaneko MK, Kato Y.
Development of an Anti-human CCR2 Monoclonal Antibody (C2Mab-9) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 188–193, https://doi.org/10.1089/mab.2022.0001, 2022 (PDF)
13. Kudo Y, Suzuki H, Kaneko MK, Kato Y.
Development of a Monoclonal Antibody PMab-295 Against Elephant Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 194–201, https://doi.org/10.1089/mab.2022.0007, 2022 (PDF)
12. Asano T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Identification of the Binding Epitope of an Anti-Mouse CCR4 Monoclonal Antibody, C4Mab-1
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 214–220, https://doi.org/10.1089/mab.2022.0015, 2022 (PDF)
11. Okada Y, Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Elephant Podoplanin Monoclonal Antibody (PMab-295) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 221–227, https://doi.org/10.1089/mab.2022.0017, 2022 (PDF)
10. Suzuki H, Ohishi T, Asano T, Tanaka T, Saito M, Mizuno T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y.
Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors
Oncol. Rep.,,48(3), 154, https://doi.org/10.3892/or.2022.8366, 2022 (PDF)
9. Saito M, Suzuki H, Kaneko MK, Kato Y.
TgMab-2: An Anti-Human TIGIT Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 157–162, https://doi.org/10.1089/mab.2022.0013, 2022 (PDF)
8. Tanaka T, Li G, Asano T, Kaneko MK, Suzuki H, Kato Y.
Epitope Mapping of the Anti-Human CCR2 Monoclonal Antibody C2Mab-9
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 150–156, https://doi.org/10.1089/mab.2022.0012, 2022 (PDF)
7. Goto N, Suzuki H, Tanaka T, Asano T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Chinese/golden Hamster Podoplanin Monoclonal Antibody
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 163–169, https://doi.org/10.1089/mab.2022.0014, 2022 (PDF)
6. Kitamura K, Suzuki H, Kaneko MK, Kato Y.
Cx6Mab-1: a Novel Anti-mouse CXCR6 Monoclonal Antibody established by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 133–141, https://doi.org/10.1089/mab.2022.0010, 2022 (PDF)
5. Li G, Suzuki H, Asano T, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
Development of A Novel Anti-EpCAM Monoclonal Antibody for Various Applications
Antibodies, 11(2), 41; https://doi.org/10.3390/antib11020041, 2022 (PDF) (Preprint)
4. Goto N, Suzuki H, Tanaka T, Asano T, Kaneko MK, Kato Y.
Development of a novel anti-CD44 monoclonal antibody for multiple applications against esophageal squamous cell carcinomas
Int. J. Mol. Sci., 23(10), 5535; https://doi.org/10.3390/ijms23105535, 2022 (PDF) (Preprint)
2021
3. Teizo Asano, Hiroyuki Suzuki, Mika K. Kaneko, Yukinari Kato.
Epitope Mapping of a Cancer-specific Anti-podocalyxin Monoclonal Antibody (PcMab-60) using Enzyme-linked Immunosorbent Assay and Surface Plasmon Resonance
Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2021.0030, 2021 (ref)
(ポドカリキシンに対するがん特異的抗体のエピトープ解析)
2020
2. Kaneko MK, Ohishi T, Kawada M, Kato Y.
A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma
Biochem Biophys Rep., 24, 100826, https://doi.org/10.1016/j.bbrep.2020.100826, 2020 (PDF)
(ポドカリキシンに対するがん特異的抗体の開発)
1. Kaneko MK, Ohishi T, Nakamura T, Inoue H, Takei J, Sano M, Asano T, Sayama Y, Hosono H, Suzuki H, Kawada M, Kato Y.*
(*corresponding author)
Development of Core-fucose Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies
Monoclon. Antib. Immunodiagn. Immunother., 39(5), 167–174, https://doi.org/10.1089/mab.2020.0019, 2020 (PDF)
(ポドプラニンに対するヒト化抗体の開発)
